Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.62 |
| ▸ | RAB9A | P51151 | 9/20 | 0.62 |
| ▸ | NPC1 | O15118 | 8/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 8/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.58 |
| ▸ | RELA | Q04206 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961699 | 0.86 | SMN1; SMN2 (0.81) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| Irampanel SCHEMBL678128 | 0.80 | HTR7 (0.63) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| SCHEMBL7956985 | 0.80 | KMT2A (0.55) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| Irampanel SCHEMBL6879876 | 0.79 | HTR7 (0.62) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| SCHEMBL7957183 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| SCHEMBL30729285 | 0.77 | SMN1; SMN2 (0.77) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| SCHEMBL3428143 | 0.77 | SMN1; SMN2 (0.77) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| Dimethylamine SCHEMBL7957188 | 0.76 | GPR55 (0.55) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| SCHEMBL7956586 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1GAATP53 | |
| SCHEMBL7958865 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | EISAI CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1100504-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | Eisai Co., Ltd. (JP) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001376-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | EISAI CO., LTD (JP) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | SMN1; SMN2 241/4885RAB9A 4547/4885NPC1 1842/4885 |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | GRIK4, GRIK5, GRIK3 | SMN1; SMN2 774/4885RAB9A 4435/4885NPC1 3963/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | SMN1; SMN2 212/4885RAB9A 4624/4885NPC1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.